Edwards, The 'Cleanest Large-Cap Medtech Story,' Launches On Second-Quarter Beat
Licensing
Edwards Lifesciences (EW) has the "cleanest large-cap medtech story," an analyst said Friday as he upgraded the stock following a strong second-quarter performance. In his upgrade, Leerink Partners analyst Mike Kratky said the heart-valve replacement maker checks nearly all the boxes. He pointed to share gains for its transcatheter aortic and mitral/tricuspid heart-valve replacements, upcoming readouts, underappreciated tailwinds and operating…
